Multiple myeloma arises from a complex interplay of acquired genetic mutations in plasma cells and, in a smaller but meaningful way, inherited genetic susceptibility. It is not a classically “inherited” cancer in the way some breast or colon cancers can be, but first-degree relatives of someone with myeloma face roughly two to four times the usual risk of developing the disease themselves. The genetic story of myeloma involves both the mutations that accumulate inside tumor cells over a person’s lifetime and the germline variants a person is born with that tilt the odds. Understanding how those two layers interact helps clarify why some people develop the disease and others do not, and why it behaves so differently from patient to patient.
How Myeloma Begins at the Genetic Level
Myeloma does not spring up overnight. It nearly always evolves from a precursor state called monoclonal gammopathy of undetermined significance, or MGUS, in which a small population of abnormal plasma cells produces an abnormal protein in the blood but causes no symptoms. Most people with MGUS never progress to myeloma. Among those who do, researchers have observed that risk scores can shift over time as the abnormal cells acquire new genetic changes, sometimes leading to abrupt jumps in risk even a year before diagnosis.1National Cancer Institute. MGUS to Myeloma: Study Suggests Risk of Progression Can Change
The earliest genetic events that set myeloma in motion fall into two broad categories. The first involves translocations of the immunoglobulin heavy chain (IgH) gene on chromosome 14. These rearrangements occur when the cell’s normal antibody-gene shuffling process goes wrong, accidentally placing a cancer-promoting gene next to the powerful IgH regulatory region, which forces the gene into overdrive. IgH translocations involving seven recurrent partner genes are found in about 40% of myeloma tumors.2PubMed Central. Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets These translocations are thought to happen during the normal antibody class-switching process, and because this same process occurs in MGUS, the rearrangement likely represents one of the very first genetic hits in the disease.3Cancer Research Therapy and Control. IgH translocations in multiple myeloma
The second founding event is hyperdiploidy, where plasma cells end up with extra copies of whole chromosomes, typically the odd-numbered ones (3, 5, 7, 9, 11, 15, 17, and 19), pushing the average chromosome count to around 53 instead of the normal 46. This shows up in roughly half of all myeloma cases.4PubMed. Hyperdiploid myeloma: The silent majority How those extra chromosomes appear is still debated, but one leading hypothesis suggests a single catastrophic cell division goes haywire, gaining multiple chromosomes at once rather than accumulating them gradually.5PubMed Central. Hyperdiploid Multiple Myeloma with Novel Complex Structural Chromosome Abnormalities Associated with Poor Prognosis These two founding events, IgH translocations and hyperdiploidy, are largely mutually exclusive. A given myeloma clone usually carries one or the other, and that initial split shapes how the disease behaves and what additional mutations it picks up later.
Secondary Genetic Changes That Drive Progression
The founding event alone is not enough to cause full-blown myeloma. Over months or years, additional genetic hits pile on and push the disease forward. Among the most common are mutations in the KRAS, NRAS, and BRAF genes, all part of a single signaling cascade called the MAPK pathway. Collectively, mutations in these three genes appear in roughly 60% of myeloma patients.6PubMed Central. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation These mutations keep growth signals permanently switched on and appear to help myeloma cells survive by reducing the internal stress that would otherwise trigger cell death.7PubMed Central. Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
Loss of the TP53 tumor suppressor gene, located on chromosome 17p, is another pivotal event. TP53 normally acts as a brake on cell growth, ordering damaged cells to stop dividing or self-destruct. Deletion of 17p is relatively rare at diagnosis, occurring in somewhere between 2% and 11% of newly diagnosed patients, but it becomes far more common in advanced or relapsed disease, appearing in up to half of patients with late-stage myeloma.8PubMed Central. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant That rising frequency over time strongly suggests TP53 loss is a key driver of disease progression rather than an initial event.
Abnormalities involving chromosome 1 also matter a great deal. A gain of the long arm of chromosome 1 (called +1q) has recently been recognized as a high-risk feature in the revised international staging system for myeloma and influences how long remissions last.9PubMed Central. Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts Meanwhile, deletion of the short arm of chromosome 1 (1p) is detected in close to 20% of patients and also carries a poor outlook.10Blood. Mir-137 and Mir-197 within Chromosome 1p Minimal Deletion Region Regulate Apoptotic Activity in Multiple Myeloma by Targeting MCL 1
Inherited Susceptibility and Familial Risk
While the mutations described above are acquired over a lifetime, the ground on which they accumulate is not the same for everyone. Multiple studies have reported that first-degree relatives of myeloma patients face a two- to four-fold increase in their own risk of developing the disease, as well as elevated rates of MGUS and some other blood cancers.11Clinical Lymphoma Myeloma and Leukemia. Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic Family pedigree analyses, case-control studies, and the well-documented racial differences in myeloma incidence all point toward an inherited component.12PubMed Central. Inherited predisposition to multiple myeloma
Genome-wide association studies have identified dozens of specific spots in the human genome that carry common variants slightly raising myeloma risk. The largest such study to date, involving about 10,900 cases and more than 366,000 controls, pinpointed 35 risk loci, 12 of them newly identified.13Nature Communications. Deciphering the genetics and mechanisms of predisposition to multiple myeloma An earlier analysis had identified eight additional loci scattered across chromosomes 6, 7, 8, 9, 10, 16, and 20.14Nature Communications. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma Each individual variant nudges risk only a tiny amount, but the cumulative burden of many such variants creates a spectrum of inherited susceptibility. People who happen to carry a large number of risk alleles start with a higher baseline probability of developing MGUS and, from there, myeloma.
A few rare inherited variants with larger effects have also been identified, including alterations in DNA repair and telomere maintenance genes. The picture that emerges is one of polygenic risk: myeloma is not a single-gene disorder passed down in families the way cystic fibrosis or sickle cell disease is, but inherited variation still creates a permissive background on which acquired mutations are more likely to cause trouble.15PubMed Central. Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications If you have a close relative with myeloma, your risk is elevated but far from certain. The vast majority of people with a family history never develop the disease.
Why African Americans Are Disproportionately Affected
One of the starkest patterns in myeloma is the roughly two-fold higher incidence among African Americans compared to white Americans. The precursor condition MGUS is also about twice as common in Black populations. Crucially, the increased risk appears to stem from a higher rate of developing MGUS in the first place, rather than a faster rate of progression from MGUS to myeloma.16Blood Cancer Journal. Addressing the disparities: the approach to the African American patient with multiple myeloma That distinction suggests genetic factors influencing the initial formation of abnormal plasma cell clones, rather than factors governing later disease evolution, drive the disparity.
Specific genetic markers support this. A hyperphosphorylated form of a protein called paratarg-7, inherited in an autosomal dominant pattern, is more prevalent among myeloma patients of African descent. Additionally, genome-wide studies in African American populations have turned up risk loci that are distinct from those found in European-ancestry populations.16Blood Cancer Journal. Addressing the disparities: the approach to the African American patient with multiple myeloma Certain ancestral-associated alleles, including one in the CCND1 gene at position 870, are enriched in African Americans with plasma cell disorders and may predispose to specific cytogenetic subtypes of the disease.17Blood. The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias Understanding these population-specific risk factors is important not only for screening but for ensuring clinical trials include diverse genetic backgrounds.
Germline Variants Meet Acquired Mutations
One question researchers are still working to untangle is exactly how inherited risk and somatic mutations interact. A plausible model is that environmental stressors like chemical exposures or radiation increase DNA damage, and individuals whose germline variants leave them with slightly impaired DNA repair capacity are less able to correct that damage, allowing mutations to accumulate more readily.18Blood Reviews. Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility Research connecting germline risk variants to actual gene expression in tumor cells has found overlap between inherited risk loci identified by genome-wide association studies and regions that regulate gene activity within myeloma cells, suggesting that some inherited variants act by subtly altering how genes are expressed in plasma cells throughout a person’s life.19bioRxiv. Germline and somatic genetic effects on gene expression and outcome in patients with Multiple Myeloma
Non-coding regulatory mutations also play a role that was underappreciated until recently. A large-scale analysis found hundreds of recurrently mutated non-coding regions in myeloma genomes that alter the expression of nearby genes, and these non-coding mutations were present in 96% of patients studied.19bioRxiv. Germline and somatic genetic effects on gene expression and outcome in patients with Multiple Myeloma This means the genetic architecture of myeloma extends well beyond the coding regions of the genome that are traditionally studied.
Epigenetic Changes and Non-Coding RNAs
Beyond changes to the DNA sequence itself, myeloma cells show widespread alterations in how genes are switched on and off through chemical modifications of DNA and its packaging proteins. These epigenetic changes, including abnormal patterns of DNA methylation, feature prominently in myeloma’s biology and can silence tumor suppressor genes or activate growth-promoting ones without altering the underlying genetic code.20PubMed. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
Non-coding RNAs add another regulatory layer. Long non-coding RNAs, which are RNA molecules that do not produce proteins, have been shown to influence tumor cell growth, survival, adhesion to the bone marrow, and resistance to treatment in myeloma.21PubMed Central. Long non‑coding RNAs in multiple myeloma Smaller non-coding RNAs called microRNAs regulate the expression of both cancer-promoting genes and tumor suppressors, and some show promise as blood-based biomarkers that could help track the disease or predict its behavior.22Leukemia Research. Roles of noncoding RNAs in multiple myeloma The practical takeaway is that myeloma is not just about which genes are broken; it is also about which genes are improperly turned up or turned down by regulatory networks that sit on top of the genetic code.
Clonal Evolution and Why Myeloma Changes Over Time
Myeloma is not a single fixed disease but a collection of genetically distinct subpopulations, or clones, that compete and evolve inside the body. Treatment exerts strong selective pressure. Single-cell sequencing of patients undergoing therapy has revealed three main trajectories after treatment: in some patients, the malignant clone is eliminated entirely; in others, the surviving clone stabilizes; and in still others, therapy selects for a resistant subpopulation that expands.23PubMed Central. Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
A systematic review of clonal evolution events preceding relapse found that MAPK pathway mutations and changes on chromosomes 1 and 17 were recurring themes in clonal diversification. Certain mutational processes also leave their fingerprints on the myeloma genome, including activity of the APOBEC family of enzymes (which normally helps fight viruses but can inadvertently mutate the cell’s own DNA) and the chemotherapy drug melphalan, which imprints a distinctive mutational signature on surviving clones.24PubMed. A systematic literature review on clonal evolution events preceding relapse in multiple myeloma This means that some of the genetic diversity in relapsed myeloma is iatrogenic, created by the very treatments used to fight the disease.
How Genetics Guide Treatment Decisions
The growing understanding of myeloma genetics has real consequences for how patients are treated. The second revision of the International Staging System (R2-ISS) now formally incorporates genetic features alongside traditional lab values to sort patients into risk categories. The system assigns weighted scores for factors including deletion of 17p, the translocation t(4;14), gain of 1q, elevated lactate dehydrogenase, and disease stage. Patients in the lowest-risk group had a median overall survival that was not reached during follow-up, while those in the highest-risk group had a median survival of about 38 months.25PubMed. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project This system has been validated in patients receiving stem cell transplants and various induction regimens, confirming that genetic risk stratification meaningfully predicts outcomes across different treatment contexts.26PubMed Central. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
Certain genetic subtypes also open the door to targeted therapies. Patients whose myeloma carries the translocation t(11;14) tend to have tumor cells that depend heavily on a survival protein called BCL-2. The drug venetoclax, a BCL-2 inhibitor, has shown strong results in this specific subgroup. In one study of relapsed or refractory t(11;14)-positive patients treated with venetoclax and dexamethasone, the response rate reached 94%, though remissions lasted a median of about 10 months.27PubMed Central. Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers This is a clear example of genetics directing treatment: without testing for t(11;14), this therapy would not be offered, and patients with different translocations would not benefit from it the same way.28PubMed Central. Targeting BCL‑2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
The Bone Marrow Environment as a Genetic Collaborator
Myeloma cells do not operate in isolation. They live in the bone marrow and depend on constant communication with the surrounding cells, including stromal cells, immune cells, and blood vessel cells. This crosstalk is increasingly recognized as essential to the disease. Myeloma cells release tiny membrane-enclosed packages called extracellular vesicles that carry proteins, RNA, and other molecules to neighboring cells, reprogramming the local environment to support tumor growth, suppress immune surveillance, and even promote drug resistance.29PubMed Central. Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives The genetic mutations inside the myeloma cell determine what cargo these vesicles carry, which in turn shapes how aggressively the tumor can remodel its surroundings. In that sense, the genetic causes of myeloma extend beyond the tumor cell itself to include how the tumor’s mutations alter its relationship with the surrounding tissue.
Monitoring Disease Through Circulating Tumor DNA
One of the more promising practical applications of myeloma genetics is the use of circulating tumor DNA, or ctDNA, as a blood-based tool for tracking the disease. Myeloma cells shed fragments of their DNA into the bloodstream, and these fragments carry the same mutations found in the bone marrow tumor. A study combining ctDNA testing with traditional bone marrow minimal residual disease (MRD) testing found that patients who tested negative on both measures had markedly better progression-free survival compared to those who were positive on either one. Patients who were both MRD-negative and ctDNA-negative had not yet reached their median progression-free survival at the time of analysis, while those positive on one or both measures had a median of about 28 months.30PubMed Central. Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients If validated in larger studies, this approach could reduce the need for repeated bone marrow biopsies and allow earlier detection of relapse through a simple blood draw, making the genetic fingerprint of a patient’s myeloma not just a diagnostic detail but an ongoing surveillance tool.